Probiotic Intervention and Its Influence on Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Acne Vulgaris Patients
NCT ID: NCT07277075
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2024-10-01
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Akkermansia Muciniphila in Acne Vulgaris
NCT06992154
Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris
NCT04596748
The Impact of Probiotics on Skin Hydration in Youth with Mild Acne
NCT05755256
Studying the Skin Microbiome and the Potential of a Topical Probiotic Cream for Patients With Acne
NCT03469076
Probiotic Supplementation IN NAFLD Patients
NCT06074094
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Recent attention has turned toward biomarkers that reflect the inflammatory activity in acne and might act as indicators of disease severity, treatment response, or prognostic risk. One such candidate is Leucine-rich alpha-2 glycoprotein 1 (LRG1).
Probiotics are live microorganisms that, when administered in sufficient quantities, can modulate the composition of the gut microbiota, helping reduce microbial dysbiosis, regulate the immune response, and decrease inflammatory mediators, thereby reducing systemic inflammatory burden, which is called the gut-skin-axis relationship.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
Participants with clinically diagnosed mild to moderate acne vulgaris (AV) based on the Glycosaminoglycans (GAGs).
Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level
Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) levels were assessed in acne vulgaris participants and healthy controls.
Control group
Apparently healthy controls matched for age and sex
Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level
Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) levels were assessed in acne vulgaris participants and healthy controls.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level
Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) levels were assessed in acne vulgaris participants and healthy controls.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Had not used systemic or topical acne therapy for at least two months or two weeks before the research, respectively.
* Participants with clinically diagnosed mild to moderate acne vulgaris (AV) based on the Global Acne Grading System (GAGS)
Exclusion Criteria
* Lactation.
* History of hypersensitivity to probiotic components.
* Smoking.
* Presence of infections.
* Autoimmune or malignant diseases.
* Receiving any systemic therapy likely to affect the microbiome or inflammatory biomarkers.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zeinab Ali Awad Menesy
MBBCH of Dermatology, Venereology and Andrology, Benha University, Benha, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha University
Banhā, Benha, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
40-10-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.